Regeneron’s Billion-Dollar Catalyst Flying Under Wall Street’s Radar Ahead of Oct. 30 Earnings

Regeneron presented Phase III data for Libtayo (cemiplimab) in skin cancer, showing a 37% reduction in death risk. Pfizer's STARBOARD trial showed Keytruda triplet therapy improved outcomes in melanoma. Both studies were discussed at ESMO 2026.

Regeneron Pharmaceuticals extended a $270m contract with the US Government to supply its Ebola therapy, Inmazeb, through 2031. The deal builds on a 2020 partnership with BARDA to maintain national emergency stockpiles. Inmazeb, approved by the FDA in 2020, has shown a 55% mortality reduction in clinical trials. Separately, Regeneron is testing a monotherapy derived from Inmazeb in the DRC.

Regeneron Pharmaceuticals extended its agreement with BARDA to supply additional Inmazeb doses for U.S. Ebola preparedness, adding $270 million in value. The deal expands a 2020 procurement agreement and runs through 2031.

Regeneron extended its agreement with BARDA by $270 million to supply additional doses of Inmazeb, an FDA-approved Ebola treatment, through 2031. The company is also advancing maftivimab in clinical trials for Bundibugyo virus disease, following promising lab and animal studies.

Regeneron extended its U.S. contract to supply Ebola treatment Inmazeb through 2031, worth $270 million. The deal with Barda ensures U.S. preparedness for Ebola outbreaks. Inmazeb is used for infections caused by Orthoebolavirus zairense. Regeneron is also developing maftivimab for the Bundibugyo strain, with no approved therapies currently available.

Regeneron (REGN) extended its agreement with BARDA to supply additional doses of its Ebola treatment, Inmazeb, through 2031. The deal is worth approximately $270 million. Inmazeb has shown a 55% mortality reduction in clinical studies. REGN stock closed at $805.02, down 1.72%.